The vast majority of patients with BRAF mutant melanoma will have objective responses or temporary disease stabilization when treated with a BRAF inhibitor; however, most patients are likely to develop resistance to treatment and relapse within the first year of therapy (median progression-free survival is approximately 5–7 months for BRAF inhibitors) [24, 25]. This evidence concerns the gene BRAF and melanoma.